Clinical Trial Update: A 12-week Randomized Study to Evaluate Oral Istradefylline in Subjects With Moderate to Severe Parkinson's Disease [Phase 3]

View source ↗

Summary

This document reports a 12-week, randomized Phase 3 study evaluating oral istradefylline as add-on therapy in adults with moderate to severe Parkinson's disease…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nourianz (istradefylline)

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Idiopathic Parkinson's Disease | Phase 3 | Status: COMPLETED | Results posted: 2020-11-20